APA

Moghetti P., Castello R., Zamberlan N., Rossini M., Gatti D., Negri C., Tosi F., Muggeo M. & Adami S. (19990421). Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist. : The Journal of clinical endocrinology and metabolism.

Chicago

Moghetti P, Castello R, Zamberlan N, Rossini M, Gatti D, Negri C, Tosi F, Muggeo M and Adami S. 19990421. Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist. : The Journal of clinical endocrinology and metabolism.

Harvard

Moghetti P., Castello R., Zamberlan N., Rossini M., Gatti D., Negri C., Tosi F., Muggeo M. and Adami S. (19990421). Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist. : The Journal of clinical endocrinology and metabolism.

MLA

Moghetti P, Castello R, Zamberlan N, Rossini M, Gatti D, Negri C, Tosi F, Muggeo M and Adami S. Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist. : The Journal of clinical endocrinology and metabolism. 19990421.